MARKET NEWS

Zai Lab & Novocure Announce Phase 2 Pilot Study Evaluating Tumor Treating Fields Together With Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
Evonik Invests $220 Million to Build New Lipid Production Facility for mRNA-based Therapies in the US
PDS Biotechnology Granted FDA Fast Track Designation for Lead Candidate
Vaxart Reports Positive Preliminary Data from Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults
Lonza Completes Dedicated Early Clinical Phase Development & Manufacturing Facility in Bend (OR)
Eagle Pharmaceuticals Announces Submission of NDA to FDA for a Beta-1 Adrenergic Blocker

  FEATURED EDITORIAL

 

  COMPANY PROFILE

Serán Bioscience is a science-first CDMO, recognized as a leader in materials science, formulation development, and pharmaceutical manufacturing. We utilize a foundation of physical and chemical science to design robust formulations and engineered solutions. Our science, quality systems, regulatory expertise, and customer service are second to none. Your drug is your future, and you need a CMC partner that’s as committed to your success as you are. Click here for more.

Video Spotlight: MilliporeSigma: Global Partner for the Manufacturing of High-Quality Lipids

  EXCLUSIVE ONLINE CONTENT

SPECIAL ROUNDTABLE - Which Trends Will Have the Most Impact on Drug Development in 2022?

SPECIAL ROUNDTABLE - Which Trends Will Have the Most Impact on Drug Development in 2022?

Drug Development & Delivery posed this question to life science leaders during a recent roundtable discussion. While their responses are varied, a common theme is that COVID-19 has left a lasting impact on the industry….

Immunocore Announces Clinical Trial Collaboration With Sanofi

Immunocore Announces Clinical Trial Collaboration With Sanofi

Immunocore Holdings Plc recently announced it has entered into a clinical trial collaboration and supply agreement with Sanofi…..

4P-Pharma & Delta 4 Join Forces to Find & Develop Treatments for a Rare Autoimmune Chronic Liver Disease

4P-Pharma & Delta 4 Join Forces to Find & Develop Treatments for a Rare Autoimmune Chronic Liver Disease

4P-Pharma and Delta 4 recently announced the signing of a collaboration agreement in which both companies will jointly identify and develop first-in-class drug candidates for a rare autoimmune chronic liver….

Teon Therapeutics Announces FDA Acceptance of IND Application for Novel, Oral Immune Checkpoint Inhibitor

Teon Therapeutics Announces FDA Acceptance of IND Application for Novel, Oral Immune Checkpoint Inhibitor

Teon Therapeutics recently announced the acceptance by the US FDA of Teon’s Investigational New Drug (IND) application for the study of TT-816. TT-816 is a novel, oral cannabinoid CB2 receptor….

Biogen & Samsung Bioepis’ & Biogen's BYOOVIZ (ranibizumab-nuna) Launches in the US

Biogen & Samsung Bioepis’ & Biogen's BYOOVIZ (ranibizumab-nuna) Launches in the US

Samsung Bioepis Co., Ltd. and Biogen Inc. recently announced BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS (ranibizumab), has been launched….

Gattefossé Strengthens its International Footprint & Breaks Ground on its Production Site in Texas

Gattefossé Strengthens its International Footprint & Breaks Ground on its Production Site in Texas

Gattefossé will break ground on its first North American manufacturing facility in Lufkin city, TX. Gattefossé as well as officials of Lufkin city will attend the ceremony. This asset will manufacture….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Protecting Workers and the Environment: Facilities and Processes Key to Safely Making Highly Potent Drug Products

WHITEPAPER - Protecting Workers and the Environment: Facilities and Processes Key to Safely Making Highly Potent Drug Products

Highly potent APIs (HPAPI) are rapidly growing in the pharmaceutical industry. Manufacturing solid oral dosage forms (SOD) containing HPAPIs requires specific knowledge, skills, and precision without compromising environmental or worker safety.

Enteris BioPharma’s HPAPI manufacturing facility was custom-built with comprehensive …

WHITE PAPER: Bring Quality OINDPs to Market Faster Than Ever Before | Proveris Scientific

WHITE PAPER: Bring Quality OINDPs to Market Faster Than Ever Before | Proveris Scientific

The Proveris by Design™ process offers a formalized approach to product development, all the while automating in vitro testing, and streamlining troubleshooting. It is an indispensable tool for successfully developing nasal spray and inhalation drug products as well as critical …

WHITE PAPER - Nanoparticles in Drug Delivery & Photothermal Therapies

WHITE PAPER - Nanoparticles in Drug Delivery & Photothermal Therapies

Nanoparticles offer multi-functional capabilities that include the ability to be tracked within the body, deliver a specific compound at a controlled rate, target a particular location, and remotely kill cells once in place due to which their use as drug …

WHITEPAPER: Optimizing Oral Drug Delivery Using Zydis® Orally Disintegrating Tablet Technology to Address Patient Challenges

WHITEPAPER: Optimizing Oral Drug Delivery Using Zydis® Orally Disintegrating Tablet Technology to Address Patient Challenges

Many patients prefer conventional tablets for the administration of medications, but some geriatric and pediatric patients and those with altered mental status and physical impairments find swallowing tablets to be difficult. Orally disintegrating tablets (ODTs), which dissolve completely without chewing …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

June 15 – Parenteral Contract Manufacturing
June 22 – Controlled Release